Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-1975

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1975). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Des Structure)

Chemical Structure (Des Structure)
Chemical structure of desvenlafaxine. The diagram displays the molecular arrangement including the aromatic ring with hydroxyl groups, cyclohexanol moiety, and the aminoethyl side chain, as well as associated carboxyl groups and water of hydration.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A geometric mean ratio chart displays pharmacokinetic variables Cmax and AUC for Desvenlafaxine under varying conditions, including mild, moderate, and severe renal and hepatic impairment, as well as population subgroups by gender and age. The chart shows changes relative to a reference value with 90% confidence intervals.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for Desvenlafaxine when coadministered with CYP3A4 inhibitor Ketoconazole. The x-axis measures change relative to reference, with values for Cmax around 1.08 and AUC around 1.43, indicating changes in drug exposure.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A forest plot chart showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of various interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole) at different doses of Desvenlafaxine (25 mg, 50 mg, 100 mg, 400 mg). The chart compares changes relative to reference values across CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 substrates.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A Kaplan-Meier curve chart showing the estimated proportion of patients with relapse over time in days from randomization. The chart compares Desvenlafaxine Extended-Release Tablets 50 mg (solid blue line) with placebo (dashed red line) in terms of relapse percentage up to about 180 days.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph showing the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets and placebo. The y-axis represents the estimated proportion of patients with relapse, and the x-axis represents time to relapse in days. The graph has two curves: a solid blue line for Desvenlafaxine Extended-Release Tablets and a dashed red line for placebo.*
FDA Label Image

Label (Lbl713351975)

Label (Lbl713351975)
Desvenlafaxine ER 25mg Tablet label from Bryant Ranch Prepack. The label includes lot number 1523487 and NDC 71335-1975-1. It references Pristiq 25mg Tablet for comparison and notes packaging by Yichang Humanwell OSD Plant. Storage instructions indicate room temperature 20-25°C (68-77°F). The label also includes a barcode and warnings to keep drugs out of children’s reach.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.